A1AR activation regulates the levels of pro-inflammatory cytokine TNF-α and of IL-6, a cytokine with both pro- and anti-inflammatory effect, in relapsing-remitting MS (RR-MS) patients. Here, IL6 is linked to myeloid sarcoma.